Research
Hormonal
Non-Hispanic Blacks have higher rates of insulin resistance and hyperinsulinemia compared to Non-Hispanic Whites, independent of adiposity, contributing to higher diabetes risk.
Biological factors like insulin resistance may be higher in Black individuals even at the same weight as White individuals. This is a risk factor for diabetes that should be monitored by a doctor.
GoodSupportsHIGH confidence
Compared with their NHW counterparts and independent of adiposity, NHBs have greater hyperinsulinemia and insulin resistance, assessed by the iv glucose tolerance test, hyperglycemic clamp, or homeostasis model assessment of insulin resistance.
Why this rating
Based on multiple studies using rigorous methods (clamps, IV glucose tolerance tests).
Source
Health Disparities in Endocrine Disorders: Biological, Clinical, and Nonclinical Factors—An Endocrine Society Scientific Statement
Sherita Hill Golden et al. · The Journal of Clinical Endocrinology & Metabolism · 2012
DOI 10.1210/jc.2012-2043
narrative_reviewCited 403×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a primary driver of type 2 diabetes risk in minority populations, and population-level interventions targeting weight loss can favorably impact endocrine health disparities.Strong
- Standard BMI and waist circumference cut-points may underestimate metabolic risk in Asian-Americans and overestimate it in Non-Hispanic Black women, necessitating ethnic-specific definitions for central obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →